OOIR: Observatory of International Research

Papers

(The H4-Index of Critical Reviews in Oncology Hematology is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Harnessing tumor metabolism during cancer treatment: A narrative review of emerging dietary approaches	168
Letter to the Editor regarding the article “A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: How to choose drugs app	163
Thrombotic microangiopathy (aHUS/iTTP) reported so far in Covid-19 patients: The virus alone or an omnium gatherum of mechanisms and etiologies?	139
Navigating management of localized prostate cancer in the geriatric population	120
Hurrying up but not rushing, acting and not reacting, good sense and not common sense: Open thoughts and reasonable doubts on COVID-19 vaccination strategies in cancer patients	106
Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II	97
A non-invasive miRNA-based approach in early diagnosis and therapeutics of oral cancer	85
Efficacy of PD-1/PD-L1 immunotherapy on brain metastatic non-small-cell lung cancer and treatment-related adverse events: A systematic review	80
Skin barrier dysfunction in cutaneous T-cell lymphoma: From pathogenic mechanism of barrier damage to treatment	75
Dysregulation of systemic immunity in colorectal cancer and its clinical applications as biomarkers and therapeutics	66
Instruments and scales for the evaluation of acute radiation dermatitis: A systematic review	60
Development of treatment strategies for advanced HER2-positive gastric cancer: Insights from clinical trials	59
A bone paradigm challenging the standard model of myeloma oncogenesis	58
Direct and indirect effects on child neurocognitive development when maternal cancer is diagnosed during pregnancy: What do we know so far?	58
Editorial Board	58
Stereotactic body radiation therapy versus conventional external beam radiation therapy for painful bone metastases: A systematic review and meta-analysis of randomized trials	55
Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era	55
Current status of locally advanced rectal cancer therapy and future prospects	53
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm	51
Mapping the research landscape of HPV-positive oropharyngeal cancer: a bibliometric analysis	50
Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study	50
Microbiome and lung cancer: carcinogenic mechanisms, early cancer diagnosis, and promising microbial therapies	49
Double agents in immunotherapy: Unmasking the role of antibody drug conjugates in immune checkpoint targeting	49
Innovations in cancer immunotherapy: A comprehensive overview of recent breakthroughs and future directions	48
The role of cGAS-STING in remodeling the tumor immune microenvironment induced by radiotherapy	46

The cytokines in tumor microenvironment: from cancer initiation-elongation-progression to metastatic outgrowth	45
Advancing tumor vaccines: Overcoming TME challenges, delivery strategies, and biomaterial-based vaccine for enhanced immunotherapy	40
Apigenin in cancer prevention and therapy: A systematic review and meta-analysis of animal models	40
First-line treatments for advanced or recurrent endometrial cancer: Systematic literature review of clinical evidence	39
Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer	38
Chemotherapy, immunotherapy, and targeted therapy for osteosarcoma: Recent advancements	38
Immunotherapy in OSCC: Current trend and challenges	37
Exosomes derived from cancer-associated fibroblasts mediate response to cancer therapy	37
TIGIT: Will it be the next star therapeutic target like PD-1 in hematological malignancies?	37
Thrombosis and cachexia in cancer: Two partners in crime?	37
The biology and treatment of leiomyosarcomas	36
Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions	36